Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Consensus

Buy

Average target

$127.00

Implied upside

—

Analysts

24

Why Is BSX Down Today? Analyst Downgrades Weigh on Medical Device Leader

Boston Scientific fell 1.66% today as multiple Wall Street analysts downgraded the stock and trimmed price targets, citing concerns that have emerged following recent company developments. The downgrades come despite the company securing FDA clearances and launching new clinical trials, suggesting analysts are reassessing the risk-reward profile of the medical device giant.

Bottom line: Boston Scientific faces a critical near-term headwind from the cyberattack incident, which appears to have triggered analyst reassessments despite solid regulatory progress and innovation milestones. Investors should monitor the scope of the cybersecurity impact, management's operational response, and clinical trial progress, as these will likely determine whether the stock can stabilize above current levels or face further weakness.